Genentech and Curis' vismodegib is submitted for FDA OK

09/12/2011 | Xconomy

Roche Holding unit Genentech is seeking FDA approval of vismodegib, a skin cancer drug developed with Curis. Clinical data show that vismodegib significantly reduces tumors in patients with basal cell carcinoma. The oral treatment works by disrupting the hedgehog biological pathway.

View Full Article in: